Bicara CMO granted 85,000 stock options
Bicara Therapeutics Inc. reported that Chief Medical Officer William Schelman received a grant of stock options covering 85,000 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Bicara Therapeutics Inc. reported that Chief Medical Officer William Schelman received a grant of stock options covering 85,000 shares of common stock. The options have an exercise price of $22.58 per share and expire on May 8, 2036.
According to the terms, the shares underlying this option vest in sixteen equal quarterly installments following May 8, 2026, contingent on his continued service. After this grant, Schelman holds options for 85,000 shares directly, reflecting a routine compensation-related award rather than an open-market trade.
Insider Trade Summary
Grant/Award: 85,000 shares
Grant/Award
1 txn
Insider
Schelman William
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 85,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 85,000 contracts (Direct)
Footnotes (1)
- F1. The shares underlying this option vest in sixteen equal quarterly installments following May 8, 2026, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Option grant size: 85,000 options
Exercise price: $22.58 per share
Expiration date: May 8, 2036
+3 more
6 metrics
Option grant size
85,000 options
Stock Option (Right to Buy) granted to CMO
Exercise price
$22.58 per share
Conversion/exercise price of granted options
Expiration date
May 8, 2036
Option expiration for the 85,000-share grant
Underlying shares
85,000 shares
Common stock underlying the stock option grant
Vesting schedule
16 equal quarterly installments
Vesting begins after May 8, 2026, subject to service
Holdings after grant
85,000 options
Total derivative shares following transaction
Key Terms
Stock Option (Right to Buy), exercise price, vesting, expiration date, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 22.5800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares underlying this option vest in sixteen equal quarterly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-05-08T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Chief Medical Officer financial
"officer_title: Chief Medical Officer"
A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Bicara Therapeutics (BCAX) disclose about William Schelman in this Form 4?
Bicara Therapeutics disclosed that Chief Medical Officer William Schelman received a grant of stock options for 85,000 shares. These options are compensation-related, not an open-market purchase or sale, and give him the right to buy common stock at a set exercise price.
How many stock options did the Bicara (BCAX) CMO receive and at what exercise price?
The Chief Medical Officer received options covering 85,000 shares of common stock with an exercise price of $22.58 per share. This award is recorded as a grant under transaction code A, representing a grant, award, or other acquisition of derivative securities.
When do William Schelman’s Bicara (BCAX) stock options vest and expire?
The options vest in sixteen equal quarterly installments following May 8, 2026, subject to his continued service on each vesting date. They have an expiration date of May 8, 2036, providing a long-dated incentive horizon for the Chief Medical Officer.
Is the Bicara (BCAX) Form 4 for William Schelman an open-market trade?
No, the Form 4 reflects a compensation grant, not an open-market trade. The transaction code A indicates a grant, award, or other acquisition of derivative securities, and the exercise price is set at $22.58 per share with vesting conditions tied to continued service.
How many Bicara (BCAX) options does William Schelman hold after this transaction?
After this grant, William Schelman holds options for 85,000 shares of Bicara common stock directly. These options were all acquired in this single grant and represent his derivative position as shown in the filing, with no additional derivative holdings listed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates